Mylab Discovery Solutions has introduced a pair of rapid point-of-care tests that hold the potential to revolutionize the detection and monitoring of dengue infections. These groundbreaking tests, known as the rapid gold test and the high-accuracy dry luminescence assay test, are poised to play a pivotal role in tracking the various stages of dengue infection.
One of the most remarkable features of these tests lies in their ability to deliver results swiftly, within a mere 15-20 minutes. This expeditious turnaround time eliminates the need for a traditional laboratory setup, making them exceptionally well-suited for regions with limited resources. In these areas, the tests can effectively support dengue screening programs, allowing for prompt and targeted interventions.
Hasmukh Rawal, Co-founder and Managing Director of Mylab, underscored the significance of these rapid point-of-care tests. He emphasized how these innovative tools provide healthcare professionals with the precision necessary for timely and accurate diagnoses. In doing so, they prove invaluable in the sphere of disease management, enabling swift and effective actions to be taken.
Key Features of Mylab’s Dengue Tests:
- Antibody Differentiation: The tests are designed to adeptly distinguish between two critical types of antibodies: IgM and IgG. This differentiation offers vital insights into the stage of dengue infection, enabling a more nuanced understanding of its progression.
- Swift Point-of-Care Testing: With the capacity to yield results within just 15-20 minutes, these tests represent a significant advancement in point-of-care diagnostics. This speed is particularly beneficial in urgent scenarios, where timely decisions can be a matter of life and death.
- High Sensitivity and Specificity: Mylab’s tests have garnered recognition for their elevated levels of sensitivity and specificity. This reputation underscores the accuracy and reliability of the results they provide, a crucial factor in effective disease management.
- Timely Infection Detection: By detecting both IgM and IgG antibodies, these tests offer a window into recent dengue virus infections. This insight is invaluable for swiftly identifying cases and initiating appropriate care measures.
- Ease of Use: The simplicity and accessibility of these tests make them well-suited for deployment in regions with limited resources. This democratization of diagnostics can significantly contribute to controlling the spread of dengue.
Rawal’s emphasis on countering the rise of dengue cases in India underscores the urgency of the situation. By equipping healthcare professionals with these cutting-edge diagnostic tools, Mylab aims to provide an effective arsenal in the fight against this challenging disease.
Positive IgM and IgG test results hold profound diagnostic implications. In primary dengue infections, detectable IgM levels emerge as early as the third day post-infection, with persistence ranging from 2 to 6 months. Following the IgM phase, dengue IgG antibodies become discernible around the seventh day of fever during the primary infection. Remarkably, these IgG antibodies can remain detectable for an extended period, potentially spanning several years.
With a mission to empower healthcare providers and professionals, Mylab is set to roll out these advanced diagnostic tools by the end of the current month. As the battle against dengue continues, these tests offer a glimmer of hope in enhancing diagnostics and disease management strategies.
Rapid point-of-care tests for Dengue – Latest News
